Is erythropoietin a survival factor for red blood cells?

Journal of the American Society of Nephrology

Volumn 7, Issue 8, 1996, Pages 1178-1182

  Polenakovic, Momir ^a,b   Sikole, Aleksandar ^a  

^a SS CYRIL AND METHODIUS UNIVERSITY OF SKOPJE   (Macedonia)

^b SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

Author keywords

Erythropoietin; Hemodialysis; Kidney failure (chronic); Red blood cell survival; Renal anemia

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ERYTHROCYTE LIFESPAN; FEMALE; HEMATOCRIT; HEMODIALYSIS; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030377624     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Eschbach JW: The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989;35:134-148.
2. Massry SG: Pathogenesis of the anemia of uremia: Role of secondary hyperparathyroidism. Kidney Int 1983;16[Suppl 24]:204-207.
3. Bogin E, Massry SG, Levi J, Djaldelli M, Bristol G, Smith J: Effect of parathyroid hormone on osmotic fragility of human erythrocytes. J Clin Invest 1982;69:1017-1025.
4. Schwartz AB, Kelch B, Terzian L, et al.: One year of rhuEPO therapy prolongs RBC survival and may stabilize RBC membranes despite natural progression of chronic renal failure to uremia and need for dialysis. ASAIO (Am Soc Artif Intern Organs) Trans 1992;M692.
5. Polenakovic M, Sikole A, Masin G, et al.: Clinical use of human recombinant erythropoietin (rhuEPO) for treatment of the anemia of end-stage renal disease-one year experience with Recormon®. Maked Med Pregled 1993;[Suppl 12]:65-74.
6. ICSH-International Committee of Standardization in Haematology: Recommended methods for red blood cell survival studies. Br J Haematol 1980;45:655-660.
7. Bogdanova V, Georgievska S, Tadzer IS: A rapid method of estimation red blood cell survival time. Macedonian Academy of Sciences and Arts. Section of Biological and Medical Sciences, Contributions XI, 1-2, 1990.
8. Sikole A, Polenakovic M, Spasovski G, Masin G: Redcell survival in chronic haemodialysis patients treated with rhuEPO [Abstract]. Nephrol Dial Transplant 1993;8:964A.
9. Polenakovic M, Sikole A: Is erythropoietin a survival factor for the red blood cells [Abstract]. Int J Artif Organs 1995;18[Suppl 8]:428A.
10. Schwartz AB, Kahn SB, Kelch B, Kim KE, Pequignot E: RBC improved survival due to recombinant human erythropoietin explains effectiveness of less frequent, low dose subcutaneous therapy. Clin Nephrol 1992;38[Suppl 5]:283-289.
11. Hughes RT, Cotes PM, Pippard MJ, et al.: Subcutaneous administration of recombinant human erythropoietin to subjects on continuous ambulatory peritoneal dialysis: An erythrokinetic assessment. Br J Haematol 1990;75:268-273.
12. Najean Y, Moynot A, Deschryver F, et al.: Kinetics of erythropoiesis in dialysis patients receiving recombinant erythropoietin treatment. Nephrol Dial Transplant 1989;4:350-355.
13. Zehnder C, Blumberg A: Human recombinant erythropoietin treatment in transfusion dependent anemic patients on maintenance hemodialysis. Clin Nephrol 1989;31:55-59.
14. Cotes PM, Pippard MJ, Reid CDL, Winearls CG, Oliver DO, Royston PJ: Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO): An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics. Q J Med 1989;70[Suppl N262]:113-137.
15. Koury MJ, Bondurant MC: Erythropoietin retards DNA breakdown and prevents programmed death in erythroid cells. Science (Washington DC) 1990;248:378.
16. Spivak JL, Pham T, Isaacs M, Hankins WD: Erythropoietin is both a mitogen and a survival factor. Blood 1991;77:1228,
17. Bondurant M, Kelley L, Koury MJ. Is erythropoietin a differentiation factor, a mitotic factor, or a survival factor? In: Bauer C, Koch KM, Scigalla P, Wieczorek L, Eds. Erythropoietin: Molecular Physiology and Clinical Applications. New York: Marcel Dekker Inc.; 1993:241-251.
18. Lerche D, Schmidt R, Zoellner K, et al.: Rheology in whole blood and in red blood cells under recombinant human erythropoietin therapy. Contrib Nephrol 1989;76:299-305.